Zivo Bioscience, Inc. Overview
Pro stress-test →Zivo Bioscience operates in the biotech and agtech sectors with an intellectual property portfolio comprised of algal and bacterial strains, biologically active molecules and complexes, production and cultivation techniques and patented or patent-pending inventions for applications in human and animal health. The company offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging.
Strategic Profile
Pro stress-test →In April 2026, ZIVO signed a commercial-scale manufacturing agreement with Cyanotech Corporation to grow, cultivate and process Zivolife™ proprietary algal biomass at a 96-acre NELHA facility with year-round cycles and GRAS-certified operations. The company began trading on the OTCID marketplace in May 2026, reflecting a transition to streamlined reporting as it advances toward commercialization.
Competitive Landscape
Pro stress-test →Competitors include Bon Opus Biosciences, BPS Bioscience, Grobest, Cargill, and Nestlé. Zivo differentiates through proprietary algal strains and bacterial platforms for niche animal health and functional nutrition applications, though it competes against larger, well-capitalized animal health companies and established functional ingredient suppliers.
Industry Context
Zivo Bioscience, Inc. operates in Algae-derived biotech for animal and human health.
Key facts
Headquarters: Troy, Michigan, US · Employees: 7 · Revenue: $209K (TTM) · Market cap: $38.6M (as of June 22, 2026)